Astellas is still struggling to close its $379M Ocata buyout

Damian Garde

When signed a deal to acquire Therapeutics in November, it expected the company's shareholders to accept its $ 8.50-a-share offer within 20 days. But a group of jilted investors has refused to budge, agitating for a better return and forcing the Japanese drugmaker to prolong the process.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS